logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5569.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5569.produswest2
Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings | Collections | MSF Science Portal

Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. One key limitation in most of these settings is a lack of clinical bacteriology laboratory capacity, which leaves medical providers without ways to accurately diagnose patient infections and to tailor antibiotic treatment accordingly.

To help fill this critical gap, MSF and partners have developed the Mini-Lab—a small-scale, standalone lab that is easy to transport, set up and operate by staff after only a short training. Its six modules are stocked with everything needed to diagnose common bloodstream and urinary tract infections and to perform antibiotic sensitivity testing using methods adapted to extremely hot climates and remote settings.

With Mini-Lab now being rolled out to selected MSF projects, here we highlight the background to its development and some of the research behind the bacteriological tests it incorporates.

Collection Content

Journal Article
|
Research

Validation of three MicroScan® antimicrobial susceptibility testing plates designed for low-resource settings

Ronat JB, Oueslati S, Natale A, Kesteman T, Elamin W,  et al.
2022-08-30 • Diagnostics
2022-08-30 • Diagnostics
Easy and robust antimicrobial susceptibility testing (AST) methods are essential in clinical bacteriology laboratories (CBL) in low-resource settings (LRS). We evaluated the Beckman Coul...
Journal Article
|
Research

Biphasic versus monophasic manual blood culture bottles for low-resource settings: an in-vitro study

Ombelet S, Natale A, Ronat JB, Kesteman T, Vandenberg O,  et al.
2021-12-13 • Lancet Microbe
2021-12-13 • Lancet Microbe
BACKGROUND
Manual blood culture bottles (BCBs) are frequently used in low-resource settings. There are few BCB performance evaluations, especially evaluations comparing them with aut...
Journal Article
|
Review

AMR in low-resource settings: Médecins Sans Frontières bridges surveillance gaps by developing a turnkey solution, the Mini-Lab

Ronat JB, Natale A, Kesteman T, Andremont A, Elamin W,  et al.
2021-10-01 • Clinical Microbiology and Infection
2021-10-01 • Clinical Microbiology and Infection
BACKGROUND
In low- and middle-income countries (LMICs), data related to antimicrobial resistance (AMR) are often inconsistently collected. Humanitarian, private and non-governmental ...
Conference Material
|
Video

Development of an all-in-one transportable clinical bacteriology laboratory: Feedback from testing the MSF Mini-Lab development project in Haiti

Ronat JB
2021-08-25 • MSF Scientific Days Asia 2021
2021-08-25 • MSF Scientific Days Asia 2021
Journal Article
|
Research

Evaluation of MicroScan bacterial identification panels for low-resource settings

Ombelet S, Natale A, Ronat JB, Vandenberg O, Hardy L,  et al.
2021-02-19 • Diagnostics
2021-02-19 • Diagnostics
Bacterial identification is challenging in low-resource settings (LRS). We evaluated the MicroScan identification panels (Beckman Coulter, Brea, CA, USA) as part of Médecins Sans Frontiè...
Journal Article
|
Commentary

The Mini-Lab: accessible clinical bacteriology for low-resource settings

Natale A, Ronat JB, Mazoyer A, Rochard A, Boillot B,  et al.
2020-06-01 • Lancet Microbe
2020-06-01 • Lancet Microbe
Journal Article
|
Commentary

Antibiotic resistance in conflict settings: lessons learned in the Middle East

Kanapathipillai R, Malou N, Hopman J, Bowman C, Yousef N,  et al.
2019-04-10 • Journal of Antimicrobial Chemotherapy
2019-04-10 • Journal of Antimicrobial Chemotherapy
Médecins Sans Frontières (MSF) has designed context-adapted antibiotic resistance (ABR) responses in countries across the Middle East. There, some health systems have been severely damag...
Journal Article
|
Commentary

Clinical bacteriology in low-resource settings: today's solutions

Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J,  et al.
2018-03-05 • Lancet Infectious Diseases
2018-03-05 • Lancet Infectious Diseases
Low-resource settings are disproportionately burdened by infectious diseases and antimicrobial resistance. Good quality clinical bacteriology through a well functioning reference laborat...

See more collections

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effect...
Drug-resistant tuberculosis (DR-TB) remains an especially deadly form of the ancient scourge of TB, while current treatments are long, toxic, and ineffective for half of all patients. Aiming to change this unacceptable status quo, in the mid-2010’s MSF and partners launched three clinical trials to test novel regimens containing the first new TB drugs in decades. On 22 December 2022 the New England Journal of Medicine published findings from TB-PRACTECAL, a three-country randomized controlled trial, showing that a shorter regimen is safer and cured 89% of DR-TB patients, compared with 52% on the standard of care. These findings have already been incorporated into the World Health Organization’s new TB treatment guidelines. A separate study shows that the new regimen is also more cost-effective. Alongside these results the content collection linked below highlights other aspects of the trial, from community engagement strategies that helped shape TB-PRACTECAL to setbacks arising from the Covid-19 pandemic. It also examines urgent challenges in scaling up access to these life-saving drugs, including affordability and patent barriers.
MSF logo
Costs, cost-effectiveness, and financing of tuberculosis trea...

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

MSF Paediatric Days 2024 abstracts
MSF Paediatric Days 2024 abstracts
On 3-4 May in Nairobi, Kenya, MSF gathered staff from our projects with experts from academia, clinical practice and the non-governmental sector to consider key issues in humanitarian paediatrics. These included: Vaccination and vaccine-preventable diseases: Amid post-Covid-19 global setbacks in child vaccination coverage, sessions spotlighted recent increases in vaccine-preventable disease outbreaks, potential new vaccination strategies and emergency responses, and MSF’s role in vaccine advocacy and catch-up campaigns. Nutrition: Talks covered the nexus of nutrition with other key conference topics, the latest malnutrition guidance and tools, and MSF’s priorities in nutritional care. Paediatric HIV: With half of all HIV-positive children globally not receiving antiretroviral therapy, presenters reviewed the latest paediatric testing/treatment recommendations and discussed barriers and potential solutions to implementation, nutritional challenges in children with HIV, and systems strengthening for preventing and monitoring paediatric HIV. Click below to read the abstracts. And stay tuned for more conference content, coming soon.
View All Collections
Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings

Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings